Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$314.42 - $351.91 $122,623 - $137,244
-390 Reduced 33.22%
784 $275,000
Q1 2023

May 05, 2023

BUY
$283.23 - $323.1 $74,206 - $84,652
262 Added 28.73%
1,174 $369,000
Q4 2022

Feb 09, 2023

BUY
$285.76 - $321.48 $2,000 - $2,250
7 Added 0.77%
912 $263,000
Q3 2022

Nov 03, 2022

BUY
$273.83 - $305.53 $247,816 - $276,504
905 New
905 $281,000
Q4 2020

Feb 11, 2021

SELL
$207.01 - $276.09 $225,640 - $300,938
-1,090 Closed
0 $0
Q3 2020

Nov 13, 2020

BUY
$255.65 - $303.1 $10,992 - $13,033
43 Added 4.11%
1,090 $297,000
Q2 2020

Aug 05, 2020

SELL
$225.48 - $295.8 $9,921 - $13,015
-44 Reduced 4.03%
1,047 $304,000
Q1 2020

May 05, 2020

BUY
$199.77 - $247.81 $5,593 - $6,938
28 Added 2.63%
1,091 $260,000
Q4 2019

Feb 03, 2020

BUY
$166.71 - $223.91 $177,212 - $238,016
1,063 New
1,063 $233,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $120B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Gilbert & Cook, Inc. Portfolio

Follow Gilbert & Cook, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gilbert & Cook, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Gilbert & Cook, Inc. with notifications on news.